2-ethylproline | 1284942-95-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-ethylproline
• 英文别名: 2-ethylpyrrolidin-1-ium-2-carboxylate
• CAS: 1284942-95-5
• 化学式: C₇H₁₃NO₂
• mdl: MFCD07388712
• 分子量: 143.186
• InChiKey: XLWGHTVXGZCNKN-UHFFFAOYSA-N

物化性质

• 沸点：
  257.0±33.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-ethylproline 在 氯化亚砜 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 生成 tert-butyl 4-chloro-2-((2-ethyl-1-((R)-2-hydroxy-3,3-dimethylbutanoyl)pyrrolidine-2-carboxamido)methyl)benzylcarbamate
  参考文献：
  名称：

  [EN] PYRROLIDINE THROMBIN INHIBITORS
  [FR] INHIBITEURS DE THROMBINE À BASE DE PYRROLIDINE

  摘要：

  本发明的化合物，可以用于抑制凝血酶和相关的血栓闭塞，其结构如下：(I)或其药学上可接受的盐，其中R是杂环或-(CR4R5)1-2NH2，其中R4和R5在每次出现时均独立地是H、C1-6烷基、-CH2F、-CHF2、CF3或-CH2OH；R1为C1-6烷基；R2为NH2、OH、NHSO2C1-6烷基或NHC(O)C1-6烷基；R3为C3-8碳环、芳基或CR6R7R8，其中R6为氢或CH3，R7为氢或CH3，R8为CH3、芳基或5-7元杂环芳基，其中芳基和5-7元杂环芳基在每次出现时均独立地未取代或单取代、双取代、三取代或四取代的卤素，所述的杂环芳基具有1、2、3或4个氮原子。

  公开号：

  WO2014025658A1

文献信息

• Cyclic G-2AllylProline in treatment of Parkinson's disease
  申请人：Brimble Anne Margaret

  公开号：US20060258663A1

  公开（公告）日：2006-11-16

  Embodiments of this invention provide methods for thereapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and/or death of dopaminergic neurons and the adverse symptoms of such degeneration and/or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.

  本发明的实施例提供了使用环状G-2-Allyl脯氨酸进行治疗性应用的方法，以治疗多巴胺能神经元失调，包括帕金森病。环状G-2-Allyl P具有神经保护作用，并具有作为治疗剂治疗由多巴胺能神经元退化和/或死亡以及此类退化和/或死亡的不良症状所特征的疾病和其他病情的效用。此类症状包括认知和运动功能的丧失。该化合物还可用于制造药物，包括片剂、胶囊和注射液，可用于治疗此类疾病。
• Neuroprotective bicyclic compouds and methods for their use
  申请人：Brimble Margaret

  公开号：US20070197511A1

  公开（公告）日：2007-08-23

  Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.

  本发明的实施例提供了与二酮哌啶有结构关系的新型环状化合物及其治疗用途的方法。这些化合物具有神经保护作用，并可作为治疗神经退行性和/或死亡等疾病、损伤和其他病况的治疗剂。这些化合物还可用于制造治疗此类疾病的药物。
• CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY
  申请人：Bickerdike Mike John

  公开号：US20110052531A1

  公开（公告）日：2011-03-03

  Embodiments of this invention provide methods for therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat peripheral neuropathies, including toxin-induced peripheral neuropathy and diabetic as well as manufacture of medicaments including tablets, capsules, and other orally active compositions containing cG-2-allylP, as well as injectable solutions that are useful for treatment of such conditions.

  本发明的实施例提供了治疗周围神经病变的方法，包括毒素诱导的周围神经病变和糖尿病性神经病变，以及制造包含cG-2-allylP的药物，包括片剂、胶囊和其他口服制剂，以及可注射的溶液，可用于治疗此类疾病。
• METHOD FOR PRODUCING OPTICALLY ACTIVE ALPHA-SUBSTITUTED PROLINE
  申请人：API CORPORATION

  公开号：US20140127762A1

  公开（公告）日：2014-05-08

  The present invention aims to provide an industrial method practically suitable for producing optically active α-substituted prolines from an acyclic ketone compound by a small number of steps under mild conditions. The present invention relates to a production method of an optically active α-substituted proline (4) and/or an optically active α-substituted prolinamide (5), including (a) reacting an acyclic ketone compound (1) with at least one selected from ammonia, an ammonium salt, primary amine and a salt of primary amine, and a cyanating agent to give a cyclic nitrogen-containing compound (2), (b) hydrating the cyclic nitrogen-containing compound (2) to give an α-substituted prolinamide (3), and (c) resolving the α-substituted prolinamide (3) by one or more of (d) enzymatical hydrolysis, (e) resolution by diastereomeric salt formation, and (f) separation by column chromatography.

  本发明旨在提供一种工业方法，以在温和条件下通过少量步骤从非环状酮化合物中生产光学活性α-取代脯氨酸的方法。本发明涉及一种光学活性α-取代脯氨酸（4）和/或光学活性α-取代脯氨酰胺（5）的生产方法，包括以下步骤：(a)将非环状酮化合物（1）与氨、铵盐、一级胺和一级胺盐和氰化试剂中的至少一种反应，得到环状含氮化合物（2）；(b)使环状含氮化合物（2）水合，得到α-取代脯氨酰胺（3）；(c)通过(d)酶解水解、(e)对映异构盐形成的分离和/或(f)柱层析分离中的一种或多种方法来分离α-取代脯氨酰胺（3）。
• METHOD FOR PRODUCING SOLID AMINO ACID
  申请人：Kaneka Corporation

  公开号：EP2810933A1

  公开（公告）日：2014-12-10

  The problem to be solved by the present invention is to ea sily and efficiently produce an amino acid having 2 to 7 carbon atoms as a high-purity solid without complicated operation, whic h is useful as a synthetic intermediate for medicines or agroche micals. The present invention is characterized in comprising a ste p of precipitating solid amino acid with high purity. In the pr esent invention, the by-produced salt composed of the sulfonic a cid and the amine was removed to the mother liquor by reacting a n amine with a sulfonic acid salt of amino acid in an aprotic pol ar solvent, or by reacting a sulfonic acid with an amine salt of amino acid in an aprotic polar solvent. The sulfonic acid salt of amino acid, for example, may be produced by reacting a N-(tert-butoxycarbonyl) amino acid with a sulfonic acid, or by reacting an amino acid tert-butyl ester we th a sulfonic acid.

  本发明要解决的问题是在不进行复杂操作的情况下，轻松高效地生产出一种具有 2 至 7 个碳原子的高纯度固体氨基酸，该氨基酸可用作药物或农用化学品的合成中间体。 本发明的特征在于包括一种沉淀高纯度固体氨基酸的方法。在本发明中，通过使胺与氨基酸的磺酸盐在非沸腾极性溶剂中反应，或使磺酸与氨基酸的胺盐在非沸腾极性溶剂中反应，将由磺酸和胺组成的副产盐除去到母液中。 例如，氨基酸的磺酸盐可通过 N-（叔丁氧羰基）氨基酸与磺酸反应，或通过氨基酸叔丁酯与磺酸反应制得。